Krystal Biotech (KRYS) Downgraded by Zacks Investment Research to Hold

Share on StockTwits

Krystal Biotech (NASDAQ:KRYS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Saturday.

According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “

Several other research analysts also recently commented on KRYS. Cowen initiated coverage on Krystal Biotech in a research note on Wednesday, December 12th. They set an “outperform” rating for the company. Cantor Fitzgerald reissued a “buy” rating and set a $34.00 target price on shares of Krystal Biotech in a research note on Wednesday, December 19th. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Krystal Biotech in a research note on Tuesday, January 15th. ValuEngine raised Krystal Biotech from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Finally, Chardan Capital boosted their target price on Krystal Biotech from $50.00 to $57.50 and gave the stock a “buy” rating in a research note on Tuesday. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $36.90.

Shares of NASDAQ KRYS opened at $21.10 on Friday. The stock has a market cap of $299.71 million, a price-to-earnings ratio of -21.75 and a beta of 0.55. Krystal Biotech has a 12 month low of $8.91 and a 12 month high of $28.75.

Several institutional investors have recently added to or reduced their stakes in KRYS. BlackRock Inc. increased its stake in shares of Krystal Biotech by 75.4% in the second quarter. BlackRock Inc. now owns 13,040 shares of the company’s stock valued at $194,000 after buying an additional 5,607 shares during the period. Acadian Asset Management LLC increased its stake in shares of Krystal Biotech by 68.5% in the third quarter. Acadian Asset Management LLC now owns 20,558 shares of the company’s stock valued at $361,000 after buying an additional 8,356 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Krystal Biotech by 69.0% in the third quarter. JPMorgan Chase & Co. now owns 36,133 shares of the company’s stock valued at $635,000 after buying an additional 14,755 shares during the period. S Squared Technology LLC acquired a new position in shares of Krystal Biotech in the third quarter valued at approximately $948,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Krystal Biotech in the third quarter valued at approximately $891,000. 43.04% of the stock is owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.

Further Reading: What economic reports are most valuable to investors?

Get a free copy of the Zacks research report on Krystal Biotech (KRYS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.